Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective
- John Kim
- 7 days ago
- 9 min read
Edited by Yoon Hang Kim MD MPH
About Dr. Kim
Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective Telemedicine
Abstract
Small intestinal bacterial overgrowth (SIBO) remains one of the more frustrating conditions in gastroenterology—not because we can't treat it, but because it keeps coming back. Standard antibiotic therapy works, but relapse rates are discouragingly high. That's why many of us in integrative medicine and functional medicine have turned to low-dose naltrexone (LDN) as an adjunctive therapy. This article examines the science behind LDN, the clinical evidence supporting its use in SIBO, and what patients are actually experiencing. While we're still waiting on the randomized controlled trials we'd all like to see, the observational data, expert clinical experience, and patient-reported outcomes are compelling enough that LDN deserves serious consideration for patients with persistent SIBO.
Keywords: Integrative Medicine, Functional Medicine, LDN, SIBO, low-dose naltrexone, small intestinal bacterial overgrowth, gut motility, immunomodulation, prokinetic therapy
Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective
Introduction
If you've treated SIBO patients, you know the pattern: antibiotics work, symptoms improve, and then—often within weeks—everything returns. Small intestinal bacterial overgrowth affects patients with bloating, abdominal pain, diarrhea or constipation, and nutrient malabsorption (Pimentel et al., 2020). The condition can lead to poor absorption of fats, proteins, carbohydrates, and calcium, raising the risk of complications like osteoporosis.
Certain populations face higher SIBO risk. Patients with chronic disease often experience more severe or recurrent symptoms. As we age, stomach acid decreases and motility slows—both risk factors. Previous abdominal surgery and structural abnormalities can impair the normal movement of waste from the small intestine into the large intestine, promoting bacterial buildup.
Conventional management relies on antibiotics (typically rifaximin), low-FODMAP diets to limit carbohydrates that feed problematic bacteria, and prokinetic agents to restore motility. The problem? About two-thirds of successfully treated cases relapse within 2.5 months on average (Lauritano et al., 2008). That's why those of us practicing integrative medicine and functional medicine look beyond the standard playbook. We see SIBO as a symptom of deeper imbalances—impaired gut motility, immune dysregulation, intestinal barrier dysfunction, and dysbiosis. Low-dose naltrexone (LDN) addresses several of these underlying issues, which is why it's become an increasingly important tool in our practices.
Understanding Low-Dose Naltrexone and Opioid Receptors
Naltrexone has been around since 1984, FDA-approved as an opioid antagonist at 50 mg doses for treating alcohol and opioid addiction. Low-dose naltrexone is a different animal entirely. At doses of 0.5 to 4.5 mg—less than 10% of the standard dose—the drug does something unexpected (Younger et al., 2014).
Here's how it works: LDN temporarily blocks opioid receptors for about four to six hours. The body responds by ramping up production of endogenous opioids—endorphins and enkephalins—natural peptides that modulate pain, immune function, and cell growth (Arata, 2018). After LDN clears, you're left with elevated endorphin levels for 18 to 20 hours. LDN also modulates toll-like receptor 4 (TLR4) pathways, producing anti-inflammatory and immune-regulating effects (Younger & Mackey, 2009).
A few practical points: the typical research dose is 4.5 mg daily. Since no commercial low-dose formulation exists, patients obtain LDN from compounding pharmacies as capsules, sublingual drops, or creams. It's contraindicated with opioid medications. And unlike traditional opioid painkillers, LDN carries no addiction or dependence risk—making it a safer long-term option. Dr. Bernard Bihari pioneered LDN for autoimmune conditions back in 1985, and research has expanded its applications considerably since then.
I should be clear: LDN use for SIBO is experimental. There are no formal guidelines or FDA approval for this indication. Our dosing and safety data come primarily from research studies and clinical experience rather than established protocols. That said, the safety profile is favorable, and the mechanistic rationale is sound.
The Functional Medicine Approach to LDN in SIBO
Those of us trained in functional medicine—whether through the Institute for Functional Medicine, the University of Arizona's integrative medicine fellowship, or similar programs—don't view SIBO as an isolated gut problem. It's a manifestation of interconnected imbalances: compromised motility, immune dysregulation, nutrient malabsorption, and disrupted gut-brain axis signaling. This perspective becomes especially valuable for complex or recurrent cases, particularly patients who also have autoimmune diseases, fibromyalgia, or other chronic inflammatory conditions.
LDN fits naturally into this framework. By modulating opioid receptors in the central nervous system, it enhances endogenous opioid production and promotes natural anti-inflammatory effects. It helps regulate immune responses by reducing proinflammatory cytokines—supporting the body's own healing capacity rather than simply suppressing symptoms.
In practice, I integrate LDN into comprehensive, individualized protocols. These typically include dietary interventions to reduce fermentable carbohydrates, targeted supplementation with fat-soluble vitamins and bile salts to optimize nutrient absorption, and prokinetic agents to address motility dysfunction. LDN often works alongside herbal antimicrobials and mind-body techniques like meditation. The goal is always to address root causes, not just manage symptoms.
Patient education matters here. I spend time explaining why we're using LDN, what realistic expectations look like based on published outcomes, and how we'll adjust dosing based on individual response. This collaborative approach—where patients become active participants in their healing—tends to produce better long-term results for SIBO and related chronic conditions.
Mechanisms of LDN Relevant to Small Intestinal Bacterial Overgrowth
Several mechanisms make LDN relevant for SIBO. First, it has prokinetic properties—it enhances the migrating motor complex (MMC), the cyclical pattern of gut motility that sweeps bacteria and debris from the small intestine between meals (Siebecker, 2023). When the MMC doesn't function properly, bacteria accumulate. This is arguably the central problem in SIBO, and LDN helps address it.
Second, LDN's immunomodulatory effects may tackle the autoimmune component of SIBO. Pimentel's research has shown that post-infectious SIBO involves autoantibodies against vinculin, a protein critical for intestinal nerve function (Pimentel et al., 2015). By modulating T-cell and B-cell activity through opioid growth factor (OGF) receptor interactions, LDN may reduce autoantibody production and help restore normal gut motility.
LDN also acts on microglial cells in the central nervous system, decreasing neuroinflammation and downregulating proinflammatory cytokines. This mechanism may affect substance P, a neuropeptide involved in pain signaling—relevant for patients with concurrent fibromyalgia or chronic pain. In fact, LDN may be one of the first glial cell modulators used for chronic pain management.
Third, LDN supports intestinal barrier integrity. The "leaky gut" associated with SIBO improves through TLR4-mediated anti-inflammatory effects, which promote mucosal healing and reduce bacterial translocation (Carnahan, 2016). Finally, by reducing the cytokine activation that perpetuates mast cell activation—a common comorbidity in complex SIBO cases—LDN addresses yet another piece of the puzzle.
Clinical Evidence and Expert Perspectives
Let me be honest about the evidence: we don't have large randomized controlled trials for LDN in SIBO specifically. What we do have is observational data, case series, and substantial expert clinical experience. Research has also explored LDN's benefits in Crohn's disease, multiple sclerosis, rheumatoid arthritis, and as a cancer treatment adjunct.
Ploesser et al. (2010) surveyed LDN use in gastrointestinal disorders and found that among patients with IBS and evidence of SIBO, 17.6% reported marked improvement and 37.6% reported moderate benefit. Overall, about 68% showed symptomatic improvement. Patients commonly report better sleep quality, reduced fatigue, improved mood, and increased mobility as pain and inflammation decrease.
Dr. Leonard Weinstock, a gastroenterologist at Washington University and medical advisor for the LDN Research Trust, has published extensively on LDN in GI conditions. His 2018 BMJ Case Reports paper documented successful treatment of POTS and mast cell activation syndrome using combined LDN, immunoglobulin, and antibiotics for concurrent SIBO (Weinstock et al., 2018). He's stated publicly that LDN is indispensable in his practice, having prescribed it to thousands of patients.
Dr. Allison Siebecker, who specializes in SIBO, includes LDN among her recommended prokinetic options for relapse prevention. It's not technically a prokinetic, but it has prokinetic effects plus additional benefits: immune balancing, inflammation reduction, mood improvement (Siebecker, 2023). Dr. Michael Ruscio uses LDN in his SIBO protocols, particularly for patients with extra-intestinal manifestations like restless leg syndrome, rosacea, and chronic fatigue. When the big names in this field are all using it, that tells you something.
Patient Community Perspectives
Patient testimonials add real-world context to the clinical data. Many patients with chronic disease or autoimmune conditions seek out LDN hoping to address multiple health concerns simultaneously. The LDN Research Trust has documented numerous patient stories where individuals report expanded dietary tolerance, reduced joint pain, and return to normal activities after years of SIBO-related restrictions (LDN Research Trust, 2023). One patient described finally being able to "expand her diet and return to regular exercise, removing the joint pain" that had plagued her.
In Weinstock's 2018 case report, a patient with severe POTS, MCAS, and SIBO wrote: "I feel like I won the lottery last year by discovering LDN, IVIg and SIBO treatment. LDN made me feel noticeably happier, more energetic, in less pain and with better digestion." Online forums like Health Rising and the Low Toxin Forum feature ongoing discussions about LDN for SIBO. Users share experiences of improved motility, reduced bloating, and better energy. A common theme: LDN requires gradual titration, and some patients do best at doses below the standard 4.5 mg target.
These reports align with what I see clinically. Individualized dosing matters. Combination protocols—LDN plus dietary interventions, antimicrobials, and other prokinetics—tend to work better than any single intervention alone.
Clinical Application of LDN in SIBO
In my practice, I typically start LDN at 0.5 to 1.5 mg at bedtime, titrating gradually over two to four weeks toward 4.5 mg based on tolerance (Weinstock, 2018). Some patients do better at lower maintenance doses—another reason individualized care matters. I often combine LDN with conventional prokinetics like low-dose erythromycin or prucalopride, herbal prokinetics such as ginger and Iberogast, rifaximin or herbal antimicrobials for bacterial reduction, and dietary interventions including low-FODMAP or elemental diets.
Side effects are generally mild: vivid dreams, insomnia, headaches, and occasionally GI upset. About 10-15% of patients experience insomnia, which often resolves with morning dosing instead. The absolute contraindication is concurrent opioid use—LDN will precipitate withdrawal. The key point I emphasize with patients: LDN is one component of comprehensive SIBO management, not a standalone cure. We're always addressing underlying causes—motility dysfunction, dietary triggers, immune dysregulation.
Conclusion
Low-dose naltrexone offers something we don't often see: a single intervention that addresses multiple SIBO-related mechanisms. Prokinetic effects, immunomodulation, anti-inflammatory activity, intestinal barrier support—it's a multitasker with a favorable safety profile. The evidence base isn't where we'd like it to be; we need randomized controlled trials specifically examining LDN for SIBO eradication and relapse prevention.
Until that research arrives, LDN remains a reasonable consideration for treatment-resistant SIBO, especially in patients with comorbid conditions like mast cell activation syndrome, POTS, or autoimmune features. We should counsel patients about off-label use while acknowledging what clinical experience consistently shows: for many patients, LDN makes a meaningful difference. In integrative medicine and functional medicine, that's often enough to warrant a thoughtful trial.
Low-Dose Naltrexone (LDN) for Small Intestinal Bacterial Overgrowth (SIBO): An Integrative and Functional Medicine Perspective
About Dr. Kim's Telemedicine Practice
At www.directintegrativecare.com, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.
Yoon Hang Kim MD
Integrative & Functional Medicine Physician
References
Arata, M. (2018). Low dose naltrexone (LDN) and small intestinal bacterial overgrowth (SIBO) [Conference presentation]. LDN Research Trust Conference.
Carnahan, J. C. (2016). Low dose naltrexone (LDN): The treatment you've never heard of. International Journal of Complementary & Alternative Medicine, 4(3), 00123. https://doi.org/10.15406/ijcam.2016.04.00123
Lauritano, E. C., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S., ... & Gasbarrini, A. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. American Journal of Gastroenterology, 103(8), 2031-2035.
LDN Research Trust. (2023). Patient testimonials and resources. https://ldnresearchtrust.org
Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. American Journal of Gastroenterology, 115(2), 165-178. https://doi.org/10.14309/ajg.0000000000000501
Pimentel, M., Morales, W., Pokkunuri, V., Brikos, C., Kim, S. M., Kim, S. E., ... & Chang, C. (2015). Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model. Digestive Diseases and Sciences, 60(5), 1195-1205.
Ploesser, J., Weinstock, L. B., & Thomas, E. (2010). Low dose naltrexone: Effects on medication in chronic pain and fatigue syndromes. International Journal of Pharmaceutical Compounding, 14(5), 360-364.
Siebecker, A. (2023). Prevention of SIBO relapse. SIBO Info. https://www.siboinfo.com/prevention-of-relapse.html
Weinstock, L. B., Brook, J. B., Myers, T. L., & Goodman, B. (2018). Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Reports, 2018, bcr-2017-221405. https://doi.org/10.1136/bcr-2017-221405
Younger, J., & Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10(4), 663-672.
Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451-459. https://doi.org/10.1007/s10067-014-2517-2
Disclaimer
This article provides an evidence-informed overview of low-dose naltrexone for SIBO within integrative and functional medicine frameworks. The information presented is for educational purposes only and does not constitute medical advice. Readers should consult qualified healthcare professionals for personalized treatment decisions. LDN use for SIBO is considered off-label and should be prescribed and monitored by appropriately trained clinicians.
Comments